FLUORESCENCE BRONCHOSCOPY

(20-Mark Answer - RGUHS Pattern)

INTRODUCTION

Reference: Fishman's Pulmonary Diseases and Disorders - "Biopsies from areas of abnormal fluorescence increase the rate of detection of small, premalignant (dysplasia) or early malignant (carcinoma in situ) lesions in the tracheobronchial tree."

I. HISTORICAL BACKGROUND

II. SCIENTIFIC BASIS / MECHANISM OF AUTOFLUORESCENCE

Principle of Autofluorescence

Key Endogenous Fluorophores

Why Tumors Fluoresce Differently

NORMAL MUCOSA                    DYSPLASTIC / MALIGNANT MUCOSA
─────────────────                ─────────────────────────────
Thin epithelium                  Thickened epithelium
                                 (more cells absorb light)
Rich submucosal collagen         Destroyed collagen architecture
(main source of green AF)        (reduced collagen fluorescence)

Blue light penetrates →          Blue light absorbed/scattered by
reaches collagen →               increased vascularity (angiogenesis)
STRONG GREEN FLUORESCENCE        REDUCED/ABSENT GREEN FLUORESCENCE

Result: GREEN on screen          Result: DARK RED/BROWN on screen

1. Increased epithelial thickness - absorbs more excitation light
2. Increased mucosal vascularity/angiogenesis - hemoglobin absorbs blue light
3. Destruction of submucosal collagen - less fluorescent material

III. DIAGRAM: FLUORESCENCE BRONCHOSCOPY PRINCIPLE

    EXCITATION LIGHT SOURCE (Blue 395-445 nm)
              │
              ▼
    ┌─────────────────────────────────────┐
    │         BRONCHIAL MUCOSA           │
    │                                     │
    │  NORMAL AREA     DYSPLASTIC AREA   │
    │  ┌──────────┐    ┌──────────────┐  │
    │  │Thin epi- │    │Thick epithe- │  │
    │  │thelium   │    │lium + angio- │  │
    │  │          │    │genesis       │  │
    │  │Intact    │    │Disrupted     │  │
    │  │collagen  │    │collagen      │  │
    │  └──────────┘    └──────────────┘  │
    └─────────────────────────────────────┘
              │                │
              ▼                ▼
    Strong GREEN AF     Weak/Absent Green AF
     emission           Dark RED/BROWN signal
              │                │
              ▼                ▼
    ┌──────────────────────────────────────┐
    │         CCD CAMERA                  │
    │   (captures composite image)        │
    └──────────────────────────────────────┘
              │
              ▼
    ┌──────────────────────────────────────┐
    │         MONITOR DISPLAY             │
    │   Normal = GREEN                    │
    │   Suspicious = DARK RED/MAGENTA     │
    └──────────────────────────────────────┘

IV. SYSTEMS / DEVICES

A. LIFE System (Lung Imaging Fluorescence Endoscope)

• Developed by Lam et al., British Columbia Cancer Agency (1991)
• Uses helium-cadmium laser (442 nm) or filtered mercury lamp as excitation source
• Detects fluorescence at two bands: green (480-520 nm) and red (630-720 nm)
• Ratio of green/red fluorescence computed
• Normal tissue: High green-to-red ratio
• Abnormal tissue: Low green-to-red ratio (decreased green, increased red)
• Combined with conventional WLB bronchoscope
• Onco-LIFE (upgraded) - uses both blue (395-445 nm) AND red (675-720 nm) reflectance light to reduce false positivity from inflammation

B. SAFE System (System of Autofluorescence Endoscopy)

• Developed by Kakihana et al. (1999)
• SAFE-1000 and SAFE-3000
• Uses a xenon lamp with blue filter (400-450 nm) as excitation
• Integrated with a video bronchoscope
• Advantage: Can perform WLB and AFB with the same scope (no scope change)
• SAFE-3000: real-time image processing with enhanced sensitivity

C. D-Light System (Karl Storz)

• Uses filtered light source (380-460 nm)
• Integrated autofluorescence capability
• Can switch between WLB and fluorescence modes
• Validated by Herth et al. (2003) - comparable performance to LIFE

D. AFI System (Autofluorescence Imaging - Olympus)

• Most widely used modern system
• Uses Evis Lucera Spectrum video bronchoscope (BF-F260)
• Three-signal composite image:
  • Autofluorescence (blue 395-445 nm excitation → 490-700 nm emission) → displayed as Green
  • Green reflected light → displayed as Red
  • Red reflected light → displayed as Blue
• Normal bronchial mucosa appears GREEN
• Abnormal/malignant mucosa appears MAGENTA or RED-PURPLE
• Advantage: No scope change needed; real-time integrated display

Comparison Table of Systems

V. INDICATIONS

1. High-risk patients for lung cancer (smokers >30 pack-years, age >45 years)
2. Sputum cytology showing atypia with normal/equivocal chest imaging
3. Surveillance after curative resection of lung cancer (detect synchronous/metachronous lesions)
4. Evaluation of radiologically occult lung cancer (ROLC)
5. Pre-operative staging - assess extent of endobronchial involvement
6. Chemoprevention trials - monitoring progression/regression of preinvasive lesions
7. Surveillance after photodynamic therapy (PDT) or endobronchial therapy
8. After head and neck cancer diagnosis (field cancerization - detect synchronous airway malignancy)
9. Known carcinoma in situ - to map extent before treatment
10. Occupational lung carcinogen exposure (asbestos, radon, arsenic workers)

VI. CONTRAINDICATIONS

• Severe respiratory failure (SpO2 <90% despite supplemental O2)
• Uncontrolled coagulopathy
• Unstable hemodynamics / severe arrhythmia
• Allergy to local anesthetic

• Recent MI (<6 weeks)
• Severe thrombocytopenia (platelets <20,000/mm³)
• Elevated ICP
• Severe asthma (active attack)

VII. PROCEDURE / TECHNIQUE

Pre-procedure

• Informed consent
• CBC, coagulation profile, ECG
• NBM (nil by mouth) 4-6 hours prior
• IV access; pulse oximetry; SpO2 monitoring

Step-by-Step Procedure (AFI System)

FLOWCHART: FLUORESCENCE BRONCHOSCOPY PROCEDURE

       PATIENT PREPARATION
              │
              ▼
    Topical anesthesia (Lidocaine 2-4%)
    + Midazolam IV sedation ± Atropine
              │
              ▼
    Position: Supine / Semi-recumbent
              │
              ▼
    WHITE LIGHT BRONCHOSCOPY (WLB) FIRST
    - Assess gross anatomy
    - Inspect vocal cords, trachea, carina
    - Assess all visible lobar/segmental bronchi
              │
              ▼
    SWITCH TO FLUORESCENCE MODE (AFB)
    - Same scope, press AFI/fluorescence button
    - Reexamine ENTIRE tracheobronchial tree
              │
    ┌─────────────────┐
    │   FINDINGS       │
    └────────┬────────┘
             │
    ┌────────┴────────────────┐
    │                         │
    ▼                         ▼
GREEN AREA              RED/MAGENTA AREA
(Normal mucosa)          (Suspicious lesion)
    │                         │
    ▼                         ▼
Continue                TARGETED BIOPSY
surveying                (2-4 forceps biopsies)
                              │
                              ▼
                     SEND FOR HISTOPATHOLOGY
                     (H&E + Immunohistochemistry)
                              │
                    ┌─────────────────────┐
                    │  PATHOLOGY RESULT   │
                    └──────────┬──────────┘
                               │
            ┌──────────────────┼──────────────────┐
            ▼                  ▼                  ▼
       Normal/mild         Moderate-severe    Carcinoma in situ /
       dysplasia           dysplasia          Invasive carcinoma
            │                  │                  │
            ▼                  ▼                  ▼
       Observation /       Close              Curative
       chemoprevention     surveillance       treatment (PDT,
       trials              (3-6 monthly)      surgery, RT)

VIII. RESULTS / WHAT IS SEEN

IX. SENSITIVITY AND SPECIFICITY

Key point (Fishman's): "Although AFB may provide the ability to localize these early lesions with greater sensitivity than white light bronchoscopy (WLB), longitudinal studies demonstrate that only 0-32% of severe dysplastic foci progress to CIS or invasive cancer; 60-65% of moderate or severe dysplastic lesions regress or resolve spontaneously."

X. ADVANTAGES

1. Greatly increased sensitivity for detecting premalignant lesions compared to WLB alone
2. Real-time diagnosis - immediate visual feedback
3. Targeted biopsies - increases diagnostic yield while reducing unnecessary biopsies
4. Non-invasive detection without exogenous dye injection
5. Can be combined with WLB using the same flexible bronchoscope (modern systems)
6. Field cancerization surveillance - detects lesions in clinically "normal" appearing mucosa
7. Guides PDT - locates lesion boundaries for photosensitizer activation
8. No radiation exposure

XI. DISADVANTAGES / LIMITATIONS

1. High false-positive rate (40-60%) - inflammation, granulation tissue, mucus plugs also appear red
2. Low specificity compared to WLB
3. Cannot visualize peripheral lesions beyond subsegmental bronchi
4. Adenocarcinoma is predominantly peripheral - not amenable to fluorescence bronchoscopy
5. Expensive equipment - limited availability in resource-poor settings
6. Operator dependent - requires experienced bronchoscopist
7. Still requires histopathological confirmation
8. Cannot grade severity of lesion by appearance alone
9. Motion artifacts degrade image quality
10. Natural history uncertainty - most dysplastic lesions regress spontaneously

XII. COMPARISON: WLB vs AFB vs NBI

         ┌───────────────────────────────────────────────────┐
         │      ADVANCED BRONCHOSCOPY MODALITIES             │
         └───────────────┬───────────────────────────────────┘
                         │
          ┌──────────────┼───────────────┐
          ▼              ▼               ▼
   WHITE LIGHT     AUTOFLUORESCENCE   NARROW-BAND
  BRONCHOSCOPY      BRONCHOSCOPY (AFB)  IMAGING (NBI)
  (WLB)             
  
  Modality:         Tissue              Hemoglobin
  Reflected white   autofluorescence    absorption at
  light             (intrinsic          415 nm
                    chromophores)
  
  Detects:          Green → RED/BROWN   Green → Brown
  Gross lesions     in dysplasia/CIS    in angiogenesis
  
  Sensitivity:      HIGH                SIMILAR to AFB
  Low (9-23%)       (50-80%)            but HIGHER
                                        Specificity
  
  Specificity:      Very high           Higher than AFB
  Very High         Low (40-60%)        (reduced false +ve)
  (95-100%)
  
  Key advantage:    Better than WLB     Detects capillary
  Baseline exam     for dysplasia       pattern - useful
                                        for ASD (abnormal
                                        surface vasculature)
  
  Best use:         Initial survey      Confirms AFB
  All patients      High-risk cases     positives

XIII. NARROW BAND IMAGING (NBI) - KEY COMPANION MODALITY

• B1 filter: 400-430 nm (closely matches hemoglobin absorption peak at 415 nm)
• B2 filter: 420-470 nm
• G filter: 560-590 nm

From Thoracic Key (Olympus AFI evidence base): "NBI was found to be useful for detecting capillary blood vessels in ASD lesions at sites of abnormal fluorescence. In a pilot study of 22 patients where WLB was performed followed by NBI, NBI identified dysplasia or malignancy not apparent on WLB in 23% of subjects."

XIV. OTHER ADVANCED IMAGING MODALITIES (Associated)

A. Optical Coherence Tomography (OCT)

• Analogous to ultrasound but uses infrared light instead of acoustic waves
• Resolves structures as small as 3 μm (superior to CT/MRI for microscopic changes)
• Real-time cross-sectional imaging
• Detects airway wall microanatomy

B. Confocal Laser Endomicroscopy (CLE)

• Fiberoptic mini-probe introduced through flexible bronchoscope
• Uses cellular autofluorescence on laser excitation
• Resolution: 3.5 μm, depth: 240 μm, field of view: 600 μm
• Offers "optical biopsy" - cellular-level imaging without tissue removal

XV. FLOWCHART: CLINICAL ALGORITHM FOR HIGH-RISK PATIENT

HIGH-RISK PATIENT
(Smoker >30 pack-years, Age >45, Sputum atypia, Previous HNSCC)
                    │
                    ▼
           CHEST CT + SPUTUM CYTOLOGY
                    │
         ┌──────────┴──────────┐
         ▼                     ▼
    SPUTUM ATYPIA          SUSPICIOUS
    + NORMAL/EQUIVOCAL     CT LESION
    IMAGING                    │
         │                     ▼
         ▼              CONVENTIONAL WLB
    WLB + AFB              (+ EBUS, TBNA,
    (Fluorescence          BAL, Biopsy)
    bronchoscopy)
         │
    ┌────┴────────────┐
    ▼                 ▼
GREEN AREA         RED/MAGENTA AREA
(Normal)           (Suspicious)
                        │
                        ▼
               TARGETED BIOPSY
                        │
          ┌─────────────┴──────────────┐
          ▼                            ▼
     BENIGN/MILD                HIGH-GRADE DYSPLASIA
     DYSPLASIA                  / CIS / CARCINOMA
          │                            │
          ▼                            ▼
  SURVEILLANCE +              CONSIDER TREATMENT:
  CHEMOPREVENTION             • Photodynamic Therapy (PDT)
  (Isotretinoin,              • Endobronchial Brachytherapy
  Anethole dithiolethione)    • Electrocautery / Cryotherapy
                              • Surgery (sleeve resection)
                              • External Beam Radiotherapy

XVI. RECENT ADVANCES (2020-2026)

1. AI-Assisted Fluorescence Bronchoscopy

• Deep learning algorithms (CNNs) trained on AFB images improve real-time lesion detection
• Reduces operator dependency and inter-observer variability
• 2025 review (PMID 40940931 - Cancers): "Integrating AI in Bronchoscopy and EBUS for Lung Cancer Diagnosis" - systematic review confirming AI augments diagnostic accuracy
• AI models can distinguish inflammation-based false-positives from true dysplasia

2. Fluorescence Lifetime Imaging (FLIM)

• Measures decay time of fluorophore emission (not just intensity)
• NADH has different lifetimes in free (0.4-0.5 ns) vs protein-bound (2.0-2.5 ns) states
• More specific - can differentiate metabolic states of cells
• FAD lifetime: ~6 ns
• Better discrimination between inflammatory and neoplastic lesions

3. Combination Modalities (AFB + NBI + OCT)

• Multi-modal platforms allow switching between AFB, NBI, OCT in a single session
• Increases both sensitivity AND specificity
• AFB localizes suspicious area → NBI confirms vascular pattern → OCT provides depth profiling

4. Robotic-Assisted Bronchoscopy

• Navigation bronchoscopy (Ion, Monarch platforms) combined with fluorescence
• Reaches peripheral lesions previously inaccessible to AFB
• Extends fluorescence detection to peripheral adenocarcinoma

5. Autofluorescence Bronchoscopy for Tumor Margin Assessment

• 2025 PMC study (PMC13077253): AFB for assessing tumor margins after neoadjuvant immunotherapy in NSCLC before surgery
• WLB + AFB combined significantly more accurate than WLB alone for margin definition
• Guides extent of surgical resection

6. Low-cost AFB Systems

• 2024 - deep learning-assisted low-cost autofluorescence microscopy for "slide-free" histological imaging
• Goal: AFB technology accessible in resource-limited settings

7. 5-ALA Photosensitizer Enhanced Fluorescence Bronchoscopy

• Exogenous 5-aminolevulinic acid (5-ALA) administered orally
• Preferentially accumulates as protoporphyrin IX (PpIX) in malignant cells
• PpIX fluoresces bright RED under blue light (635 nm) - dramatically improves sensitivity
• Distinguishes from autofluorescence-based systems

XVII. REFERENCES (Standard Textbooks Referenced)

XVIII. SUMMARY TABLE (For Quick Revision)

MNEMONICS

KEY EXAMINATION POINTS (RGUHS 20 Marks)

1. Define fluorescence bronchoscopy and explain the scientific basis of autofluorescence (5 marks)
2. Describe the LIFE and AFI systems with diagram (4 marks)
3. Indications and contraindications (3 marks)
4. Procedure with flowchart (3 marks)
5. Advantages, limitations, and comparison with WLB (3 marks)
6. Recent advances including NBI, OCT, AI (2 marks)